Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
Identifieur interne : 000B25 ( PubMed/Corpus ); précédent : 000B24; suivant : 000B26Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
Auteurs : Shuetsu Fukushi ; Aiko Fukuma ; Takeshi Kurosu ; Shumpei Watanabe ; Masayuki Shimojima ; Kazuya Shirato ; Naoko Iwata-Yoshikawa ; Noriyo Nagata ; Kazuo Ohnishi ; Manabu Ato ; Simenew Keskes Melaku ; Hiroshi Sentsui ; Masayuki SaijoSource :
- Journal of virological methods [ 1879-0984 ] ; 2018.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (blood), Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (isolation & purification), Antibodies, Viral (immunology), Antibodies, Viral (isolation & purification), Camelus, Enzyme-Linked Immunosorbent Assay (methods), Middle East Respiratory Syndrome Coronavirus (immunology), Rabbits, Rats, Sensitivity and Specificity, Spike Glycoprotein, Coronavirus (immunology).
- MESH :
- chemical , blood : Antibodies, Monoclonal.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Viral, Spike Glycoprotein, Coronavirus.
- chemical , isolation & purification : Antibodies, Monoclonal, Antibodies, Viral.
- immunology : Middle East Respiratory Syndrome Coronavirus.
- methods : Enzyme-Linked Immunosorbent Assay.
- Animals, Camelus, Rabbits, Rats, Sensitivity and Specificity.
Abstract
Since discovering the Middle East respiratory syndrome coronavirus (MERS-CoV) as a causative agent of severe respiratory illness in the Middle East in 2012, serological testing has been conducted to assess antibody responses in patients and to investigate the zoonotic reservoir of the virus. Although the virus neutralization test is the gold standard assay for MERS diagnosis and for investigating the zoonotic reservoir, it uses live virus and so must be performed in high containment laboratories. Competitive ELISA (cELISA), in which a labeled monoclonal antibody (MAb) competes with test serum antibodies for target epitopes, may be a suitable alternative because it detects antibodies in a species-independent manner. In this study, novel MAbs against the spike protein of MERS-CoV were produced and characterized. One of these MAbs was used to develop a cELISA. The cELISA detected MERS-CoV-specific antibodies in sera from MERS-CoV-infected rats and rabbits immunized with the spike protein of MERS-CoV. The MAb-based cELISA was validated using sera from Ethiopian dromedary camels. Relative to the neutralization test, the cELISA detected MERS-CoV-specific antibodies in 66 Ethiopian dromedary camels with a sensitivity and specificity of 98% and 100%, respectively. The cELISA and neutralization test results correlated well (Pearson's correlation coefficients=0.71-0.76, depending on the cELISA serum dilution). This cELISA may be useful for MERS epidemiological investigations on MERS-CoV infection.
DOI: 10.1016/j.jviromet.2017.10.008
PubMed: 28993122
Links to Exploration step
pubmed:28993122Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.</title><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan. Electronic address: fukushi@nih.go.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Fukuma, Aiko" sort="Fukuma, Aiko" uniqKey="Fukuma A" first="Aiko" last="Fukuma">Aiko Fukuma</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Kurosu, Takeshi" sort="Kurosu, Takeshi" uniqKey="Kurosu T" first="Takeshi" last="Kurosu">Takeshi Kurosu</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Watanabe, Shumpei" sort="Watanabe, Shumpei" uniqKey="Watanabe S" first="Shumpei" last="Watanabe">Shumpei Watanabe</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Shimojima, Masayuki" sort="Shimojima, Masayuki" uniqKey="Shimojima M" first="Masayuki" last="Shimojima">Masayuki Shimojima</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name><affiliation><nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><affiliation><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><affiliation><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name><affiliation><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name><affiliation><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Melaku, Simenew Keskes" sort="Melaku, Simenew Keskes" uniqKey="Melaku S" first="Simenew Keskes" last="Melaku">Simenew Keskes Melaku</name><affiliation><nlm:affiliation>Department of Biotechnology, College of Biological and Chemical Engineering, Addis Ababa Science and Technology University, Ethiopia.</nlm:affiliation></affiliation></author><author><name sortKey="Sentsui, Hiroshi" sort="Sentsui, Hiroshi" uniqKey="Sentsui H" first="Hiroshi" last="Sentsui">Hiroshi Sentsui</name><affiliation><nlm:affiliation>Department of Veterinary Medicine, Nihon University, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:28993122</idno><idno type="pmid">28993122</idno><idno type="doi">10.1016/j.jviromet.2017.10.008</idno><idno type="wicri:Area/PubMed/Corpus">000B25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B25</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.</title><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan. Electronic address: fukushi@nih.go.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Fukuma, Aiko" sort="Fukuma, Aiko" uniqKey="Fukuma A" first="Aiko" last="Fukuma">Aiko Fukuma</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Kurosu, Takeshi" sort="Kurosu, Takeshi" uniqKey="Kurosu T" first="Takeshi" last="Kurosu">Takeshi Kurosu</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Watanabe, Shumpei" sort="Watanabe, Shumpei" uniqKey="Watanabe S" first="Shumpei" last="Watanabe">Shumpei Watanabe</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Shimojima, Masayuki" sort="Shimojima, Masayuki" uniqKey="Shimojima M" first="Masayuki" last="Shimojima">Masayuki Shimojima</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Shirato, Kazuya" sort="Shirato, Kazuya" uniqKey="Shirato K" first="Kazuya" last="Shirato">Kazuya Shirato</name><affiliation><nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><affiliation><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><affiliation><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name><affiliation><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Ato, Manabu" sort="Ato, Manabu" uniqKey="Ato M" first="Manabu" last="Ato">Manabu Ato</name><affiliation><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Melaku, Simenew Keskes" sort="Melaku, Simenew Keskes" uniqKey="Melaku S" first="Simenew Keskes" last="Melaku">Simenew Keskes Melaku</name><affiliation><nlm:affiliation>Department of Biotechnology, College of Biological and Chemical Engineering, Addis Ababa Science and Technology University, Ethiopia.</nlm:affiliation></affiliation></author><author><name sortKey="Sentsui, Hiroshi" sort="Sentsui, Hiroshi" uniqKey="Sentsui H" first="Hiroshi" last="Sentsui">Hiroshi Sentsui</name><affiliation><nlm:affiliation>Department of Veterinary Medicine, Nihon University, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><affiliation><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of virological methods</title><idno type="eISSN">1879-0984</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (blood)</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (isolation & purification)</term><term>Antibodies, Viral (immunology)</term><term>Antibodies, Viral (isolation & purification)</term><term>Camelus</term><term>Enzyme-Linked Immunosorbent Assay (methods)</term><term>Middle East Respiratory Syndrome Coronavirus (immunology)</term><term>Rabbits</term><term>Rats</term><term>Sensitivity and Specificity</term><term>Spike Glycoprotein, Coronavirus (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Camelus</term><term>Rabbits</term><term>Rats</term><term>Sensitivity and Specificity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since discovering the Middle East respiratory syndrome coronavirus (MERS-CoV) as a causative agent of severe respiratory illness in the Middle East in 2012, serological testing has been conducted to assess antibody responses in patients and to investigate the zoonotic reservoir of the virus. Although the virus neutralization test is the gold standard assay for MERS diagnosis and for investigating the zoonotic reservoir, it uses live virus and so must be performed in high containment laboratories. Competitive ELISA (cELISA), in which a labeled monoclonal antibody (MAb) competes with test serum antibodies for target epitopes, may be a suitable alternative because it detects antibodies in a species-independent manner. In this study, novel MAbs against the spike protein of MERS-CoV were produced and characterized. One of these MAbs was used to develop a cELISA. The cELISA detected MERS-CoV-specific antibodies in sera from MERS-CoV-infected rats and rabbits immunized with the spike protein of MERS-CoV. The MAb-based cELISA was validated using sera from Ethiopian dromedary camels. Relative to the neutralization test, the cELISA detected MERS-CoV-specific antibodies in 66 Ethiopian dromedary camels with a sensitivity and specificity of 98% and 100%, respectively. The cELISA and neutralization test results correlated well (Pearson's correlation coefficients=0.71-0.76, depending on the cELISA serum dilution). This cELISA may be useful for MERS epidemiological investigations on MERS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28993122</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0984</ISSN><JournalIssue CitedMedium="Internet"><Volume>251</Volume><PubDate><Year>2018</Year><Month>01</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J. Virol. Methods</ISOAbbreviation></Journal><ArticleTitle>Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.</ArticleTitle><Pagination><MedlinePgn>22-29</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0166-0934(17)30582-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jviromet.2017.10.008</ELocationID><Abstract><AbstractText>Since discovering the Middle East respiratory syndrome coronavirus (MERS-CoV) as a causative agent of severe respiratory illness in the Middle East in 2012, serological testing has been conducted to assess antibody responses in patients and to investigate the zoonotic reservoir of the virus. Although the virus neutralization test is the gold standard assay for MERS diagnosis and for investigating the zoonotic reservoir, it uses live virus and so must be performed in high containment laboratories. Competitive ELISA (cELISA), in which a labeled monoclonal antibody (MAb) competes with test serum antibodies for target epitopes, may be a suitable alternative because it detects antibodies in a species-independent manner. In this study, novel MAbs against the spike protein of MERS-CoV were produced and characterized. One of these MAbs was used to develop a cELISA. The cELISA detected MERS-CoV-specific antibodies in sera from MERS-CoV-infected rats and rabbits immunized with the spike protein of MERS-CoV. The MAb-based cELISA was validated using sera from Ethiopian dromedary camels. Relative to the neutralization test, the cELISA detected MERS-CoV-specific antibodies in 66 Ethiopian dromedary camels with a sensitivity and specificity of 98% and 100%, respectively. The cELISA and neutralization test results correlated well (Pearson's correlation coefficients=0.71-0.76, depending on the cELISA serum dilution). This cELISA may be useful for MERS epidemiological investigations on MERS-CoV infection.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fukushi</LastName><ForeName>Shuetsu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan. Electronic address: fukushi@nih.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuma</LastName><ForeName>Aiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurosu</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Shumpei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimojima</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirato</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Virology III, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata-Yoshikawa</LastName><ForeName>Naoko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Noriyo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohnishi</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ato</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Immunology, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melaku</LastName><ForeName>Simenew Keskes</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, College of Biological and Chemical Engineering, Addis Ababa Science and Technology University, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sentsui</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, Nihon University, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saijo</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002162" MajorTopicYN="N">Camelus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Competitive ELISA</Keyword><Keyword MajorTopicYN="Y">Epidemiology</Keyword><Keyword MajorTopicYN="Y">MERS coronavirus</Keyword><Keyword MajorTopicYN="Y">Neutralizing antibody</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>10</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28993122</ArticleId><ArticleId IdType="pii">S0166-0934(17)30582-7</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2017.10.008</ArticleId><ArticleId IdType="pmc">PMC7113858</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Jul;87(14):7790-2</Citation><ArticleIdList><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2012 Feb;19(2):277-83</Citation><ArticleIdList><ArticleId IdType="pubmed">22190400</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2014 Jun 12;19(23):</Citation><ArticleIdList><ArticleId IdType="pubmed">24957744</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biologicals. 2017 Mar;46:168-171</Citation><ArticleIdList><ArticleId IdType="pubmed">28111083</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2014 Aug;20(8):1370-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25062254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Negl Trop Dis. 2016 Apr 05;10(4):e0004595</Citation><ArticleIdList><ArticleId IdType="pubmed">27045364</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2017 May 16;14(5):e1002300</Citation><ArticleIdList><ArticleId IdType="pubmed">28510604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Cell. 2012 Nov;3(11):803-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23143870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2015 Mar 15;60(6):973-4</Citation><ArticleIdList><ArticleId IdType="pubmed">25516193</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Infect. 2014 May;20(5):469-74</Citation><ArticleIdList><ArticleId IdType="pubmed">24460984</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 Jun;15(6):629</Citation><ArticleIdList><ArticleId IdType="pubmed">26008827</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Jpn J Infect Dis. 2016 Nov 22;69(6):510-516</Citation><ArticleIdList><ArticleId IdType="pubmed">27000459</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2013 Sep 05;18(36):pii=20574</Citation><ArticleIdList><ArticleId IdType="pubmed">24079378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microbiol Immunol. 2009 Feb;53(2):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19291090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2013 Feb;187(2):424-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23174163</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Sep 15;6:8223</Citation><ArticleIdList><ArticleId IdType="pubmed">26370782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 2015 Sep;160(9):2293-300</Citation><ArticleIdList><ArticleId IdType="pubmed">26138557</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2014 Aug 28;371(9):828-35</Citation><ArticleIdList><ArticleId IdType="pubmed">25162889</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2015 Apr;4(4):e26</Citation><ArticleIdList><ArticleId IdType="pubmed">26421268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2012 Sep 27;17(39):</Citation><ArticleIdList><ArticleId IdType="pubmed">23041020</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2014 Dec 19;194:175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">24670324</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Jpn J Infect Dis. 2015;68(3):256-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25993975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Dec;21(12):2197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">26584223</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Euro Surveill. 2013 Apr 04;18(14):20441</Citation><ArticleIdList><ArticleId IdType="pubmed">23594517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2006 Dec;78(12):1509-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17063504</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 2003 Mar;108(1):111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12565161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2005 Aug;86(Pt 8):2269-2274</Citation><ArticleIdList><ArticleId IdType="pubmed">16033974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Ecol Epidemiol. 2016 Jul 04;6:31343</Citation><ArticleIdList><ArticleId IdType="pubmed">27388698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B25 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000B25 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28993122
|texte= Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28993122" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |